Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathway

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 6, 2013, Pages 2187-2192

  Varghese, Binny V ^a   Koohestani, Faezeh ^a   McWilliams, Michelle ^a   Colvin, Arlene ^a   Gunewardena, Sumedha ^a   Kinsey, William H ^a   Nowak, Romana A ^b   Nothnick, Warren B ^a   Chennathukuzhi, Vargheese M ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 10; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROLACTIN RELEASING FACTOR; PROTEIN KINASE B; REST PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEIOMYOMA CELL; MOUSE; MYOMETRIAL HYPERPLASIA; MYOMETRIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; REPRESSOR GENE; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UTERUS DISEASE; UTERUS MYOMA;

ANIMALS; BASE SEQUENCE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; LEIOMYOMA; MICE; MICE, TRANSGENIC; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 84873448916     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1215759110     Document Type: Article

References (51)

1. Walker CL, Stewart EA (2005) Uterine fibroids: The elephant in the room. Science 308 (5728):1589-1592.
2. Cardozo ER, et al. (2011) The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 206(3):211, e1-e9.
3. Stewart EA, Morton CC (2006) The genetics of uterine leiomyomata: What clinicians need to know. Obstet Gynecol 107(4):917-921.
4. Taran FA, Brown HL, Stewart EA (2009) Racial diversity in uterine leiomyoma clinical studies. Fertil Steril 94(4):1500-1503.
5. Gross KL, et al. (2004) Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: Genetic linkage analysis and FISH studies. Genes Chromosomes Cancer 41(3):183-190.
6. Mäkinen N, et al. (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334(6053):252-255.
7. Navarro A, et al. (2012) Genome-wide DNA methylation indicates silencing of tumor suppressor genes in uterine leiomyoma. PLoS ONE 7(3):e33284.
8. Pan Q, Luo X, Chegini N (2010) microRNA 21: Response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. Mol Hum Reprod 16(3):215-227.
9. Luo X, Chegini N (2008) The expression and potential regulatory function of micro-RNAs in the pathogenesis of leiomyoma. Semin Reprod Med 26(6):500-514.
10. Pan Q, Luo X, Chegini N (2008) Differential expression of micro RNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med 12(1):227-240.
11. Peng L, et al. (2009) Expression of insulin-like growth factors (IGFs) and IGF signaling: Molecular complexity in uterine leiomyomas. Fertil Steril 91(6):2664-2675.
12. Wei JJ, et al. (2006) Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod 21(1):57-67.
13. Crabtree JS, et al. (2009) Comparison of human and rat uterine leiomyomata: Identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 69 (15):6171-6178.
14. Cook JD, Walker CL (2004) The Eker rat: Establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma. Curr Mol Med 4(8):813-824.
15. Karra L, et al. (2010) Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. Fertil Steril 93(8):2646-2651.
16. Gu W, Geddes BJ, Zhang C, Foley KP, Stricker-Krongrad A (2004) The prolactin-releasing peptide receptor (GPR10) regulates body weight homeostasis in mice. J Mol Neurosci 22(1-2):93-103.
17. Lin SH (2008) Prolactin-releasing peptide. Results Probl Cell Differ 46:57-88.
18. Lawrence CB, Celsi F, Brennand J, Luckman SM (2000) Alternative role for prolactinreleasing peptide in the regulation of food intake. Nat Neurosci 3(7):645-646.
19. Samson WK, et al. (2003) Prolactin-releasing peptide and its homolog RFRP-1 act in hypothalamus but not in anterior pituitary gland to stimulate stress hormone secretion. Endocrine 20(1-2):59-66.
20. Samson WK, Taylor MM (2006) Prolactin releasing peptide (PrRP): An endogenous regulator of cell growth. Peptides 27(5):1099-1103.
21. Kemp DM, Lin JC, Ubeda M, Habener JF (2002) NRSF/REST confers transcriptional repression of the GPR10 gene via a putative NRSE/RE-1 located in the 5′ promoter region. FEBS Lett 531(2):193-198.
22. Hayakawa J, et al. (2002) Regulation of the PRL promoter by Akt through cAMP response element binding protein. Endocrinology 143(1):13-22.
23. Westbrook TF, et al. (2008) SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452(7185):370-374.
24. Westbrook TF, et al. (2005) A genetic screen for candidate tumor suppressors identifies REST. Cell 121(6):837-848.
25. Weissman AM (2008) How much REST is enough? Cancer Cell 13(5):381-383.
26. Coulson JM (2005) Transcriptional regulation: Cancer, neurons and the REST. Curr Biol 15(17):R665-668.
27. Palm K, Metsis M, Timmusk T (1999) Neuron-specific splicing of zinc finger transcription factor REST/NRSF/XBR is frequent in neuroblastomas and conserved in human, mouse and rat. Brain Res Mol Brain Res 72(1):30-39.
28. Langmead CJ, et al. (2000) Characterization of the binding of [(125)I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor. Br J Pharmacol 131(4):683-688.
29. Bhattacharyya S, et al. (2003) Association of polymorphisms in GPR10, the gene encoding the prolactin-releasing peptide receptor with blood pressure, but not obesity, in a U.K. Caucasian population. Diabetes 52(5):1296-1299.
30. Romagnolo B, et al. (1996) Tissue-specific and hormonal regulation of calbindin-D9K fusion genes in transgenic mice. J Biol Chem 271(28):16820-16826.
31. Kawaguchi K, et al. (1991) Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol 419(4):309-315.
32. Shimojo M, Hersh LB (2006) Characterization of the REST/NRSF-interacting LIM domain protein (RILP): Localization and interaction with REST/NRSF. J Neurochem 96(4): 1130-1138.
33. Watanabe A, et al. (2007) Altered emotional behaviors in the diabetes mellitus OLETF type 1 congenic rat. Brain Res 1178:114-124.
34. Bechtold DA, Luckman SM (2006) Prolactin-releasing peptide mediates cholecystokinin-induced satiety in mice. Endocrinology 147(10):4723-4729.
35. Laurent P, et al. (2005) The prolactin-releasing peptide antagonizes the opioid system through its receptor GPR10. Nat Neurosci 8(12):1735-1741.
36. Nieminen ML, Brandt A, Pietilä P, Panula P (2000) Expression of mammalian RF-amide peptides neuropeptide FF (NPFF), prolactin-releasing peptide (PrRP) and the PrRP receptor in the peripheral tissues of the rat. Peptides 21(11):1695-1701.
37. Distefano G, et al. (2009) Polycystin-1 regulates extracellular signal-regulated kinasedependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 29(9):2359-2371.
38. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16(12): 1472-1487.
39. Ruvinsky I, Meyuhas O (2006) Ribosomal protein S6 phosphorylation: From protein synthesis to cell size. Trends Biochem Sci 31(6):342-348.
40. Bronson MW, Hillenmeyer S, Park RW, Brodsky AS (2010) Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells. Mol Endocrinol 24(6):1120-1135.
41. Liu Z, Liu M, Niu G, Cheng Y, Fei J (2009) Genome-wide identification of target genes repressed by the zinc finger transcription factor REST/NRSF in the HEK 293 cell line. Acta Biochim Biophys Sin (Shanghai) 41(12):1008-1017.
42. Abrajano JJ, et al. (2010) Corepressor for element-1-silencing transcription factor preferentially mediates gene networks underlying neural stem cell fate decisions. Proc Natl Acad Sci USA 107(38):16685-16690.
43. Cheong A, et al. (2005) Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell 20(1):45-52.
44. Lunyak VV, et al. (2002) Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 298(5599):1747-1752.
45. Guardavaccaro D, et al. (2008) Control of chromosome stability by the beta-TrCPREST-Mad2 axis. Nature 452(7185):365-369.
46. Nibert M, Heim S (1990) Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer 2(1):3-13.
47. Ding N, et al. (2008) Mediator links epigenetic silencing of neuronal gene expression with x-linked mental retardation. Mol Cell 31(3):347-359.
48. McGuire MM, et al. (2012) Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS ONE 7(3):e33251.
49. Hunter DS, et al. (2002) Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function. Cancer Res 62(13): 3766-3772.
50. Velagaleti GV, et al. (2010) Fusion of HMGA2 to COG5 in uterine leiomyoma. Cancer Genet Cytogenet 202(1):11-16.
51. Mesquita FS, et al. (2010) Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol Reprod 82(2): 341-351.